BG Medicine, Inc. (BGMD)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jan 21, 2025, 4:00 PM EST
BG Medicine Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | 2010 - 2006 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '15 Dec 31, 2015 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 | Dec '11 Dec 31, 2011 | 2010 - 2006 |
| Revenue | 1.57 | 1.57 | 2.79 | 4.07 | 2.82 | 1.63 | Upgrade
|
| Revenue Growth (YoY) | -43.81% | -43.81% | -31.57% | 44.69% | 72.28% | 99.51% | Upgrade
|
| Cost of Revenue | 0.51 | 0.51 | 0.96 | 1.39 | 0.96 | 0.62 | Upgrade
|
| Gross Profit | 1.06 | 1.06 | 1.83 | 2.68 | 1.86 | 1.02 | Upgrade
|
| Selling, General & Admin | 3.86 | 3.86 | 6.52 | 13.32 | 17 | 10.5 | Upgrade
|
| Research & Development | 1.68 | 1.68 | 2.27 | 3.74 | 7.58 | 8 | Upgrade
|
| Operating Expenses | 5.53 | 5.53 | 8.79 | 17.06 | 24.59 | 18.5 | Upgrade
|
| Operating Income | -4.47 | -4.47 | -6.96 | -14.37 | -22.73 | -17.49 | Upgrade
|
| Interest Expense | -0.16 | -0.16 | -0.73 | -1.17 | -1.08 | -0.09 | Upgrade
|
| Interest & Investment Income | - | - | 0 | 0.02 | 0.02 | 0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.51 | -0.51 | 0.02 | -0.32 | 0.02 | -0.04 | Upgrade
|
| EBT Excluding Unusual Items | -5.15 | -5.15 | -7.66 | -15.85 | -23.77 | -17.58 | Upgrade
|
| Merger & Restructuring Charges | -0.16 | -0.16 | -0.4 | - | - | - | Upgrade
|
| Pretax Income | -5.3 | -5.3 | -8.06 | -15.85 | -23.77 | -17.58 | Upgrade
|
| Net Income | -5.3 | -5.3 | -8.06 | -15.85 | -23.77 | -17.58 | Upgrade
|
| Preferred Dividends & Other Adjustments | 1.66 | 1.66 | - | - | - | 0.12 | Upgrade
|
| Net Income to Common | -6.96 | -6.96 | -8.06 | -15.85 | -23.77 | -17.7 | Upgrade
|
| Shares Outstanding (Basic) | 10 | 10 | 8 | 7 | 5 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 10 | 8 | 7 | 5 | 4 | Upgrade
|
| Shares Change (YoY) | 17.53% | 17.53% | 20.18% | 34.61% | 14.62% | 493.59% | Upgrade
|
| EPS (Basic) | -0.72 | -0.72 | -0.99 | -2.33 | -4.70 | -4.01 | Upgrade
|
| EPS (Diluted) | -0.72 | -0.72 | -0.99 | -2.33 | -4.70 | -4.01 | Upgrade
|
| Free Cash Flow | -3.67 | -3.67 | -8.17 | -15.42 | -21.42 | -15.06 | Upgrade
|
| Free Cash Flow Per Share | -0.38 | -0.38 | -1.00 | -2.27 | -4.24 | -3.42 | Upgrade
|
| Gross Margin | 67.75% | 67.75% | 65.70% | 65.90% | 66.00% | 62.12% | Upgrade
|
| Operating Margin | -285.63% | -285.63% | -249.66% | -352.91% | -807.39% | -1070.07% | Upgrade
|
| Profit Margin | -444.32% | -444.32% | -289.34% | -389.12% | -844.37% | -1083.23% | Upgrade
|
| Free Cash Flow Margin | -234.16% | -234.16% | -293.04% | -378.59% | -760.85% | -921.60% | Upgrade
|
| EBITDA | -4.39 | -4.39 | -6.83 | -14.21 | -22.46 | -17.07 | Upgrade
|
| EBITDA Margin | -280.08% | -280.08% | -244.96% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.09 | 0.09 | 0.13 | 0.17 | 0.27 | 0.42 | Upgrade
|
| EBIT | -4.47 | -4.47 | -6.96 | -14.37 | -22.73 | -17.49 | Upgrade
|
| EBIT Margin | -285.63% | -285.63% | -249.66% | - | - | - | Upgrade
|
| Revenue as Reported | 1.57 | 1.57 | 2.79 | 4.07 | 2.82 | 1.63 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.